Clinical trials: Advanced Biliary Tract Cancer

Biliary Tract Cancer

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

• Unknown status
• Age: 19 to 80 years
• Phase 2/3

This study is designed to assess the antitumor activity of combination therapy of SMT-NK (allogeneic natural killer cells) and pembrolizumab versus pembrolizumab monotherapy in patients with advanced biliary tract cancer

Trial name

NCT05429697

Testing

SMT-NK inj.+Pembrolizumab, Pembrolizumab

Where

3 sites in South Korea

Volunteers

128 people

Sponsor

SMT bio Co., Ltd.